NCT06142188View on ClinicalTrials.gov

Relmacabtagene Autoleucel in Hematologic Malignancies

Not yet recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

December 31, 2038

Study Completion Date

December 31, 2038

Conditions
Lymphoma, B-CellLarge B-cell LymphomaFollicular Lymphoma
Interventions
BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Trial Locations (2)

100010

Beijing Cancer Hospital, Beijing

Peking University International Hospital, Beijing

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

NCT06142188 - Relmacabtagene Autoleucel in Hematologic Malignancies | Biotech Hunter | Biotech Hunter